<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187263</url>
  </required_header>
  <id_info>
    <org_study_id>DZHK TORCH 001</org_study_id>
    <nct_id>NCT02187263</nct_id>
  </id_info>
  <brief_title>German Centre for Cardiovascular Research Cardiomyopathy Register</brief_title>
  <acronym>TORCH</acronym>
  <official_title>DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum f√ºr Herz- Und Kreislauf-Forschung (DZHK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mainz University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Hannover</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department for Community Medicine, University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Institute Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Klinikum Rechts der Isar Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a joint project by Heidelberg University and Greifswald University.

      Our objective is to establish an unique national multi-center registry and biobank of well
      phenotyped patients with non-ischemic cardiomyopathies (CMP) including in depth clinical,
      molecular and omics-based phenotyping to serve as:

        1. central hub for clinical outcome studies.

        2. joint resource for diagnostic and therapeutic trials.

        3. common biomaterial bank.

        4. resource for detailed molecular analyses on patients' biomaterials and patient specific
           model systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following basic research projects, called modules, will be tied to and rely on the
      recruitment of CMP patients and the infrastructure provided by TORCH:

        -  Well phenotyped patients will be the starting point for comprehensive next-generation
           genotyping, leading to advanced estimates of genotype-phenotype relationship and its
           clinical impact.

        -  Functional analysis of novel genomic loci and their related molecular pathways will be
           based on our established in-vitro (e.g. iPS cells, yeast two hybrid) and in-vivo (e.g.
           zebrafish and mice) model systems.

        -  The integrated analysis of viral load and replication, inflammation, genotype and
           clinical variables will define risk variables for inflammatory and hereditary CMP.

        -  By longitudinal follow-up of patients, the role of genetic, epigenetic, metabolic,
           molecular biomarkers and histopathology for diagnosis and out-come prediction will be
           defined on a national level.

      The registry will also facilitate investigator initiated clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Acute Myocarditis</condition>
  <condition>Dilated Cardiomyopathies</condition>
  <condition>Hypertrophic Cardiomyopathies</condition>
  <condition>Left Ventricular Myocardial Noncompaction Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathies</condition>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>hereditary DCM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>inflammatory DCM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>LVNC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HCM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ARVC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>acute myocarditis</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA, serum, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hereditary and inflammatory cardiomyopathies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primary non-ischemic cardiomyopathies including hereditary and
             inflammatory dilated cardiomyopathy, left ventricular non-compaction cardiomyopathy,
             hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and
             acute myocarditis.

        Exclusion Criteria:

          -  Preexisting other cardiac diseases such as significant valvular, ischemic or
             pericardial disease; Severe arterial hypertension; Primary pulmonary artery
             hypertension; Chronic advanced disorders; History of treatment with cardiotoxic agents
             and chest radiation; Drug and alcohol abuse; Patients &lt;18 and &gt;79 years of age; Life
             expectancy less than 1 year due to non-cardiac comorbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo A Katus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Hoffmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department for Community Medicine, University Medicine Greifswald</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas O Doesch, MD</last_name>
      <phone>49 622156</phone>
      <phone_ext>39936</phone_ext>
      <email>Andreas.Doesch@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hereditary cardiomyopathy,</keyword>
  <keyword>inflammatory cardiomyopathy,</keyword>
  <keyword>registry,</keyword>
  <keyword>biomaterial,</keyword>
  <keyword>clinical trial</keyword>
  <keyword>Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

